Clinical Trial » Intervention type » Drug

Drug

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease
24 Aug 2010
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist. The purpose of Part 1 (first 26 weeks) is to determine if ... 
Responses: 1
A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
16 Aug 2010
This is a study to determine the efficacy, safety, and tolerability of nebicapone, a COMT inhibitor, to treat PD. ... 
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
16 Aug 2010
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease. ... 
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With PD Requiring Initiation of Levodopa Therapy (STRIDE-PD)
18 Jul 2010
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in ... 
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
08 Jul 2010
Parkinson's disease (PD) is the second most common neurodegenerative disease in the US, affecting nearly 1 million Americans. Up to 82% of community dwelling individuals with PD complain of ... 
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy
31 May 2010
This study was designed to assess whether GPI 1485 has the ability to delay or stop disease progression and improve symptoms in patients with Parkinson's disease (PD) that is already being ... 
Sarizotan in the Treatment of Neuroleptic-Induced Tardive Dyskinesia
31 May 2009
TD is a troublesome and potentially irreversible side effect associated with the use of neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry the ... 
Sarizotan in Parkinson Patients With L-Dopa-Induced Dyskinesia
31 May 2009
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship ... 
A Study of T2000 in Essential Tremor
31 May 2009
This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over a 20 week period. Essential tremor (ET) is a common form of ... 
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease
31 May 2009
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in ... 
Syndicate content